Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from NATCO Pharma Limited ( (IN:NATCOPHARM) ).
Natco Pharma Limited has had its credit ratings reaffirmed by ICRA Limited, reflecting its healthy financial profile, robust debt metrics, and strong liquidity position. Despite facing competition-induced pricing pressures in domestic and US markets, the company is mitigating these challenges through new product launches and expanding its presence in emerging markets. However, the impending patent expiry of gRevlimid in FY2026 poses potential volatility in revenues and margins. The company’s operating profit margin improved in FY2025 but faced contraction in FY2026 due to increased R&D spending and pricing pressures. The company’s high product concentration, increasing working capital intensity, and scrutiny by the US FDA are noted as key sensitivities.
More about NATCO Pharma Limited
Natco Pharma Limited is a prominent player in the pharmaceutical industry, known for its strong portfolio of complex generics and a notable market position in the domestic oncology formulations segment. The company benefits from robust research and development capabilities and a backward-integrated operation with strong capabilities in active pharmaceutical ingredients (APIs).
Average Trading Volume: 90,279
Technical Sentiment Signal: Buy
Current Market Cap: 158B INR
For detailed information about NATCOPHARM stock, go to TipRanks’ Stock Analysis page.